Abacavir indications and usage: Difference between revisions
Jump to navigation
Jump to search
Gerald Chi (talk | contribs) (Created page with "__NOTOC__ {{Abacavir}} {{CMG}} ==References== {{Reflist}} {{FDA}} Category:Antibiotics Category:Wikinfect") |
Ahmed Zaghw (talk | contribs) No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Abacavir}} | {{Abacavir}} | ||
{{CMG}} | {{CMG}}; {{AE}} {{AZ}} | ||
==INDICATIONS AND USAGE== | |||
ZIAGEN Tablets and Oral Solution, in combination with other antiretroviral agents, are indicated for the treatment of human immunodeficiency virus (HIV-1) infection. | |||
Additional important information on the use of ZIAGEN for treatment of HIV-1 infection: | |||
ZIAGEN is one of multiple products containing abacavir. Before starting ZIAGEN, review medical history for prior exposure to any abacavir-containing product in order to avoid reintroduction in a patient with a history of hypersensitivity to abacavir.<ref name="Dellinger-2013">{{Cite journal | last1 = Dellinger | first1 = RP. | last2 = Levy | first2 = MM. | last3 = Rhodes | first3 = A. | last4 = Annane | first4 = D. | last5 = Gerlach | first5 = H. | last6 = Opal | first6 = SM. | last7 = Sevransky | first7 = JE. | last8 = Sprung | first8 = CL. | last9 = Douglas | first9 = IS. | title = Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. | journal = Intensive Care Med | volume = 39 | issue = 2 | pages = 165-228 | month = Feb | year = 2013 | doi = 10.1007/s00134-012-2769-8 | PMID = 23361625 }}</ref> | |||
Revision as of 21:08, 30 December 2013
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]
INDICATIONS AND USAGE
ZIAGEN Tablets and Oral Solution, in combination with other antiretroviral agents, are indicated for the treatment of human immunodeficiency virus (HIV-1) infection.
Additional important information on the use of ZIAGEN for treatment of HIV-1 infection:
ZIAGEN is one of multiple products containing abacavir. Before starting ZIAGEN, review medical history for prior exposure to any abacavir-containing product in order to avoid reintroduction in a patient with a history of hypersensitivity to abacavir.[1]
References
- ↑ Dellinger, RP.; Levy, MM.; Rhodes, A.; Annane, D.; Gerlach, H.; Opal, SM.; Sevransky, JE.; Sprung, CL.; Douglas, IS. (2013). "Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012". Intensive Care Med. 39 (2): 165–228. doi:10.1007/s00134-012-2769-8. PMID 23361625. Unknown parameter
|month=ignored (help)
Adapted from the FDA Package Insert.